Search results

Epstein Barr virus (EBV) is known as an oncovirus and associates with several human malignancies such as Burkitt's lymphoma, other non-Hodgkin lymphomas, nasopharyngeal carcinoma, Hodgkin's disease, gastric adenocarcinoma, etc. in Burkitt's lymphoma, and the key event is the translocation of MYC gene, that increase of cell survival and aberrant expression of MYC gene. The biology of EBV and its function in the development of Burkitt's lymphoma are discussed in this review

The prevalence of human papillomavirus (HPV) infections and their role in cervical cancer have been well documented in numerous articles, but it seems that a study in this field in developing countries and the Middle East, including Iran. It's not done. Therefore, the present study was designed and performed to investigate the frequency and genotyping of human papillomavirus in patients by DNA tracking technique. This study was a population-based study in which the frequency and genotyping of human papillomavirus in patients by tracking technique was designed and performed on 534 men and women living in Tehran by DNA tracking technique. Sequences obtained using the NCBI site were analyzed at (http://www.ncbi.nlm.nih.gov/BLAST/LaserGene) and Bio edit software. So that in three low-risk groups including 6 and 11 genotypes, Intermediate risk includes 26-31-33-35-39-40-42-45-49-51-52-53 genotypes -55-56-58-59-66-63-83 and High risk includes 16 and 18 genotypes were divided. According to the results, the prevalence of the papilloma virus in the study population was 21.16%, of which 19.46% were in the high-risk group, 69.89% were in the intermediate-risk group and 50.43% were in the low-risk group. According to the results of the present study, although the prevalence of HPV in the study population is less than in many countries in the world, it is suggested that conducting epidemiological studies in the country to extract the true prevalence and plan to prevent and control this disease.

Every year we see many changes in the world around us. One of these changes is the climate and weather, and it could be one of the reasons for changing behaviors between humans and animals, which could cause zoonotic diseases. We usually face new diseases that infect a growing population leading to a pandemic. Different reasons are leading to an increase in the emergence of new infections. Some of these diseases can be associated with zoonotic diseases and the diverse world of viral genetics and its failures. Furthermore, properties like mutations and also unknown effects of these mutations on the virulence of the agents make it challenging to trace new diseases. As we know, preventing emerging diseases is inevitable and viral diseases are dangerous, and some viruses can spread quickly and cause an endemic or pandemic. As was noticed during the recent pandemic, the need to study emerging diseases in the field of virology has become more and more apparent to us. In this review, we want to look at how we could monitor and control these diseases with new approaches and what should be done when a disease emerges. Moreover, we will investigate risk factors, ways to deal with emerging viral infections, new treatments that make the condition better when a person gets infected, and the future of these diseases. We will also study the ways to deal with pandemics with the new generations of vaccines

The prevalence of coronavirus disease 2019 (COVID-19) is the third registered spillover of an animal coronavirus to humans from the early 21st century. Coronaviruses are important human and animal pathogens. The 2019 novel coronavirus (2019-nCoV) rapidly spreads, resulting in an epidemic throughout China, followed by an increasing number of cases in other countries throughout the world. Recently, a wide range of inhibitors have been introduced for treatment of COVID-19, and also promising vaccines are in late phase of development. Here, we aim to present an overview of recent findings of the biological and clinical aspects of SARS-CoV-2 infection, along with possible treatments and future vaccines.

"A rare zoonotic disease, monkeypox is brought on by the Monkeypox virus, which is a member of the Orthopoxvirus genus, Chordopoxvirinae subfamily, and Poxviridae family. Smallpox-like symptoms are brought on by the monkeypox disease, which is closely linked to the variola virus (smallpox virus). In the past, it has been demonstrated that smallpox vaccination with the vaccinia virus (another orthopoxvirus) is 85% protective against monkeypox. The two most likely forms of monkeypox transmission are animal-human transmission and human-human transmission. Transmission between people has been connected to respiratory droplets, coming into contact with bodily fluids, contaminated patient things or surroundings, and skin lesions on infected people. Numerous strategies or tactics have been developed by monkeypox to subvert or exacerbate the host's immune reaction to infection. A crucial element of innate immunity, natural killer [NK] cells employ cytokines to kill virus-infected cells and interfere with the operation of other cell types like T cells and dendritic cells. Studies have shown that the smallpox vaccine provides cross-protection against other Orthopoxvirus species, including monkeypox. This study was out to provide a thorough overview of the pathogenesis, prevention, risks, immune response problems, and analysis of possible concerns associated with the monkeypox virus."

Background: Coronavirus disease 2019 (COVID-19) was recognized by the World Health Organization (WHO) as a global pandemic on March 11, 2020. Since then, researchers worldwide have focused their attention on identifying effective treatments and developing vaccines to combat this disease. Aim: To report the effectiveness of the drugs employed in the COVID-19 treatment protocols based on data from clinical trial studies conducted from the beginning of the pandemic until December 10, 2020. Methods: Following the PRISMA guidelines, we conducted an advanced search in several electronic databases. A total of 13553 studies was screened by two people simultaneously and separately based on the article title, abstract and full-text. The quality of the studies was evaluated using the Cochrane criteria. Results: Of the 13553 studies identified, 50 clinical trials were included in this systematic review. Of these, three studies explored the use of remdesivir, nine studies the use of hydroxychloroquine, five studies the use of lopinavir/ritonavir, six studies the use of favipiravir, one study the use of tocilizumab, two studies the use of interferon beta-1a and two studies the use of umifenovir.

Chronic hepatitis can resolve spontaneously or progress to more advanced stages, i.e. fibrosis, cirrhosis, and liver cancer, respectively. Two million deaths each year are attributed to liver diseases globally. Chronic liver disease and cirrhosis comprise 11th position in leading causes of death worldwide. Viral infections account for the etiologic factor of most cases of hepatitis. Almost the only available way for the treatment of end stages of hepatitis is liver transplantation. The biggest problem with this therapeutic approach is the number of liver transplant donors is less than the number of recipients. Therefore, more advanced methods must investigate. Recently, gene therapy by the utilization of stem cells yielded promising results in clinical and preclinical investigations to the treatment of liver diseases. Novel genome editing tools such as TALENs and CRISPR/Cas9 consider as powerful genome correction approaches and can employe for iPSCs gene editing. This paper highlights the various aspects of gene therapy through stem cells for liver diseases.

Background and Aim: This study aimed to investigate the expression level of Sine oculis homeobox homolog 1(SIX1) in normal and cancerous cervical tissues. Methods: Real-time PCR was used to evaluate SIX1 expression level in fresh surgically obtained cervical biopsies. Also, cervical specimens were tested for HPV DNA detection by MY09/11, GP5+/6+ nested PCR method. Results: The expression level of SIX1 mRNA in Cervical cancer was markedly higher than in normal cervical tissue (p<0.0001). Moreover, HPV DNA was detected in 100% of cases and 21.05% of controls (P<0.0001). Conclusions: This finding indicates that increased SIX1 expression might be of relevance to the pathogenesis of cervical cancer. Perhaps, studies to find agents that specifically target SIX1, develop novel anti-cancer and anti-metastasis drugs. This idea has to be investigated in future clinical studies.